Table 1.
Baseline demographic and clinical characteristics of PD patients with sleep disturbances
| Characteristic | PPX SR, n=59 | PPX IR, n=60 |
|---|---|---|
| Men, n (%) | 27 (45.8) | 33 (55.0) |
| Age, years, mean (SD) | 60.8 (9.9) | 60.9 (10.1) |
| Race, n (%) | ||
| White | 31 (52.5) | 31 (51.7) |
| Asian | 28 (47.5) | 29 (48.3) |
| BMI, kg/m2, mean (SD) | 24.4 (4.4) | 24.6 (3.7) |
| Duration of illness, years, mean (SD) | 6.9 (4.7) | 8.0 (4.9) |
| On-time Hoehn and Yahr stage, n (%) | ||
| 2–3 | 57 (96.6) | 58 (96.7) |
| 4–5 | 2 (3.4) | 2 (3.3) |
| Off-time Hoehn and Yahr stage, n (%) | ||
| 2–3 | 48 (81.4) | 39 (65.0) |
| 4–5 | 11 (18.6) | 21 (35.0) |
| Concomitant PD therapies, n (%) | 59 (100.0) | 60 (100.0) |
| Levodopa | 59 (100.0) | 60 (100.0) |
| Amantadine | 9 (15.3) | 19 (31.7) |
| MAO-B inhibitors | 8 (13.6) | 12 (20.0) |
| Entacapone | 0 (0.0) | 8 (13.3) |
| Levodopa daily dosage, mg, mean (SD)a | 658.9 (372.9) | 713.5 (360.9) |
| UPDRS total scores, mean (SD) | ||
| Part I | 2.3 (1.9) | 2.3 (1.8) |
| Part II | 14.7 (6.6) | 14.4 (5.6) |
| Part III | 31.4 (13.5) | 29.7 (13.4) |
| Part II+III | 46.2 (18.9) | 44.1 (17.8) |
| Part IV | 5.9 (2.7) | 6.3 (2.7) |
Note:
a
The sample size was n=42 for PPX SR and n=56 for PPX IR.
Abbreviations: BMI, body mass index; IR, immediate release; MAO-B, monoamine oxidase type B; PD, Parkinson’s disease; PPX, pramipexole; SR, sustained release; UPDRS, Unified Parkinson’s Disease Rating Scale.